122 related articles for article (PubMed ID: 3485230)
1. [New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP].
Jonsson G; Sundström E
Lakartidningen; 1986 Jan; 83(4):215-8. PubMed ID: 3485230
[No Abstract] [Full Text] [Related]
2. [Pethidine and parkinsonism. 1-Metyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a new neurotoxin].
Hunskår S
Tidsskr Nor Laegeforen; 1986 Jan; 106(3):219-20. PubMed ID: 3485316
[No Abstract] [Full Text] [Related]
3. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
Hirata Y; Nagatsu T
Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
[No Abstract] [Full Text] [Related]
5. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals.
Donnan GA; Kaczmarczyk SJ; Solopotias T; Rowe P; Kalnins RM; Vajda FJ; Mendelsohn FA
Clin Exp Neurol; 1986; 22():155-64. PubMed ID: 3495376
[TBL] [Abstract][Full Text] [Related]
6. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Matsubara K
Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
[TBL] [Abstract][Full Text] [Related]
7. A simple quantitative bradykinesia test in MPTP-treated mice.
Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
[TBL] [Abstract][Full Text] [Related]
8. Functional recovery in parkinsonian monkeys treated with GDNF.
Gash DM; Zhang Z; Ovadia A; Cass WA; Yi A; Simmerman L; Russell D; Martin D; Lapchak PA; Collins F; Hoffer BJ; Gerhardt GA
Nature; 1996 Mar; 380(6571):252-5. PubMed ID: 8637574
[TBL] [Abstract][Full Text] [Related]
9. 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Finnegan KT; Irwin I; Delanney LE; Ricaurte GA; Langston JW
J Pharmacol Exp Ther; 1987 Sep; 242(3):1144-51. PubMed ID: 3498815
[TBL] [Abstract][Full Text] [Related]
10. MPTP: a pharmacological tool to study parkinsonism.
Kulkarni SK; Mehta AK; Aley KO; Shukla VK
Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Rajeswari A; Sabesan M
Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
[TBL] [Abstract][Full Text] [Related]
12. [Etiopathogeny of Parkinson disease. The MPTP revolution].
Sampaio C; Castro Caldas A
Acta Med Port; 1988; 1(4-6):304-7. PubMed ID: 3073646
[No Abstract] [Full Text] [Related]
13. The MPTP model of Parkinson's disease.
Smeyne RJ; Jackson-Lewis V
Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
[TBL] [Abstract][Full Text] [Related]
14. Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism.
Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y
Nucl Med Biol; 2009 Aug; 36(6):623-9. PubMed ID: 19647168
[TBL] [Abstract][Full Text] [Related]
15. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Sayre LM
Toxicol Lett; 1989 Aug; 48(2):121-49. PubMed ID: 2672418
[TBL] [Abstract][Full Text] [Related]
16. [L-threo-DOPS therapy and parkinsonism].
Narabayashi H
No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
[No Abstract] [Full Text] [Related]
17. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
[TBL] [Abstract][Full Text] [Related]
18. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
19. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
Liberatore GT; Jackson-Lewis V; Vukosavic S; Mandir AS; Vila M; McAuliffe WG; Dawson VL; Dawson TM; Przedborski S
Nat Med; 1999 Dec; 5(12):1403-9. PubMed ID: 10581083
[TBL] [Abstract][Full Text] [Related]
20. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
